This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned, following a “positive” September meeting with FDA. “We’re excited, we think this is great news”, Compass CEO Kabir Nath told Psychedelic Alpha this morning. “This is a potential acceleration by…
